SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy
SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients Future studies needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk … Read more